Recipharm Acquires Vibalogics, Arranta Bio

Recipharm, a global contract development and manufacturing organization (CDMO), has acquired Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners. Vibalogics holds a leading position in the manufacture of oncolytic viruses, viral vaccines, and gene therapies, providing process and analytical development, manufacturing, testing, and fill-finish services.

Vibalogics continues to respond to the rapidly growing biopharmaceutical industry demand for specialized CDMO capabilities for the manufacture of live viruses and viral vectors, including herpes viruses, pox viruses, adenoviruses, and other viral classes for cancer and other applications. Continued investment, including its recent expansion in Germany and the U.S., has positioned Vibalogics to support the full product lifecycle of its clients, including commercial supply.

The deal will provide Recipharm with capabilities in new biologics modalities, leveraging Vibalogics’ expertise in oncolytic viruses, viral vaccines, and viral vector gene therapies to bring a high degree of diversification across multiple technologies and modalities.

Recipharm also has acquired Arranta Bio, an advanced therapy CDMO, which has an established, strong service portfolio and is a leader in delivering microbiome therapeutic products and mRNA clinical production capabilities.

Arranta Bio has a strong microbiome platform with fermentation and purification expertise for naturally derived and engineered bacteria consortia, complemented by services in analytics, proprietary media, and cryopreservative formulations. In addition, Arranta Bio has been progressing the supply of end-to-end mRNA capabilities across drug substance and drug product under one roof, providing substantial time savings in product manufacturing and a hedge against supply chain challenges.

The acquisition of Arranta establishes a robust U.S. presence for Recipharm and provides the company with a further platform from which to build its capabilities in new biologics modalities, leveraging Arranta’s expertise in advanced therapies to bring a high degree of diversification across multiple technologies and modalities.